OakChart

Clene Inc

CLNNHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 2:38 PM ET

4.27-0.14 (-3.17%)
2026-11-11 20:39 CET
Market cap
63.50 USD m
Revenue, TTM
0.24 USD m
Net income, TTM
-26.83 USD m
Free cash flow, TTM
-16.67 USD m
EPS diluted, TTM
-2.61
P/E
-
Compare

Price

CLNN against its 20, 50 and 200-day averages
2050200beatmiss
4.006.00240K479KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CLNNclose 4.2720-day 3.8550-day 3.90200-day 5.144.2752w low

60.6% under the 52-week high of 10.84 on 28 Nov 2025. 52-week low 3.02 on 16 Oct 2026. Last 15 sessions, 36.8% high to low

Profile

CLNN
52-week range, 16% of the way up
3.0210.84

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Employees79
IPOAug 27, 2018
Beta1.03
ATR, 14d0.37
Rel volume1.87
Short float3.64%
Insider own20.39%
Inst own17.46%

Snapshot

6 groups

Valuation

Index-
Market Cap61.48M
Enterprise Value74.19M
Income-26.83M
Sales0.24M
Book/sh-1.04
Cash/sh0.69
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees79
IPOAug 27, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S256.18
P/B-
P/C6.22
P/FCF-
EV/EBITDA-
EV/Sales309.14
Quick Ratio0.84
Current Ratio0.85
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.61
EPS next Y-1.49
EPS next Q-0.47
EPS this Y18.04%
EPS next Y31.22%
EPS next 5Y-
EPS past 3/5Y33.86% 34.50%
Sales past 3/5Y-24.94% -0.59%
EPS Y/Y TTM30.44%
Sales Y/Y TTM11.21%
EPS Q/Q105.71%
Sales Q/Q273.33%
EarningsNov 04 BMO
EPS/Sales Surpr.111.01% -20.00%

Ownership

Insider Own20.39%
Insider Trans-3.15%
Inst Own17.46%
Inst Trans-4.87%
ROA-120.65%
ROE-
ROIC-
Gross Margin-526.89%
Oper. Margin-8928.57%
Profit Margin-11271.43%
SMA2010.95%
SMA509.44%
SMA200-16.92%
Trades-

Technical

Shs Outstand14.21M
Shs Float11.46M
Short Float3.64%
Short Ratio3.88
Short Interest0.42M
52W High10.84 -60.61%
52W Low3.02 41.62%
Volatility14.67% 9.70%
ATR (14)0.37
RSI (14)58.24
Beta1.03
Rel Volume1.87
Avg Volume107.47K
Volume161,169

Performance

Perf Week4.15%
Perf Month25.96%
Perf Quarter1.91%
Perf Half Y-34.31%
Perf YTD-27.26%
Perf Year-55.29%
Perf 3Y-52.56%
Perf 5Y-96.14%
Perf 10Y-
Recom1.00
Target Price32.20
Prev Close4.41
Price4.27
Change %-3.17%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Oct 04, 2022DowngradeOOppenheimerOutperform → Perform
Jul 18, 2022InitiatedHH.C. WainwrightBuy$16+274.7%
May 02, 2022InitiatedCCanaccord GenuityBuy$10+134.2%
Sep 28, 2021InitiatedOOppenheimerOutperform$20+368.4%

Peers

Mkt cap
TickerCompanyMkt cap
COYACoya Therapeutics Inc77.06M
MNOVMedicinova Inc69.16M
PMNProMIS Neurosciences Inc34.66M
INMBINmune Bio Inc35.29M
ANVSAnnovis Bio Inc35.56M
DNLIDenali Therapeutics Inc3.16B
CGTXCognition Therapeutics Inc64.12M
CRVOCervoMed Inc26.93M
BIIBBiogen Inc37.53B
AMLXAmylyx Pharmaceuticals Inc4.06B

Insider trading

latest 14 of 71
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ugwumba Chidozie10% OwnerMay 12 '26Sale6.2073,296454,435103,417May 13 06:04 PM
Ugwumba Chidozie10% OwnerMay 11 '26Sale6.7522,177149,695176,713May 13 06:04 PM
Symbiosis II LLCFormer Board MemberMay 11 '26Proposed Sale6.50198,8901,292,785May 11 04:15 PM
Ugwumba Chidozie10% OwnerMay 04 '26Sale6.8072,884495,611198,890May 05 05:53 PM
Ugwumba Chidozie10% OwnerMay 01 '26Sale6.015,79534,828271,774May 05 05:53 PM
Symbiosis II LLCFormer Board MemberMay 04 '26Proposed Sale6.5541,260270,381May 04 04:02 PM
Ugwumba Chidozie10% OwnerApr 29 '26Sale5.6312,17068,517283,305Apr 30 05:54 PM
Ugwumba Chidozie10% OwnerApr 30 '26Sale6.085,73634,875277,569Apr 30 05:54 PM
Ugwumba Chidozie10% OwnerApr 28 '26Sale5.901,5919,387295,475Apr 30 05:54 PM
Symbiosis II LLCFormer Board MemberApr 28 '26Proposed Sale5.9056,916335,804Apr 28 04:10 PM
Ugwumba Chidozie10% OwnerApr 21 '26Sale6.1461,345376,658297,066Apr 22 05:55 PM
Ugwumba Chidozie10% OwnerApr 20 '26Sale6.124,31826,426358,411Apr 22 05:55 PM
Ugwumba Chidozie10% OwnerApr 17 '26Sale6.4325,040161,007362,729Apr 17 08:17 PM
Ugwumba Chidozie10% OwnerApr 16 '26Sale6.407,74849,587387,769Apr 17 08:17 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights (GlobeNewswire) +8.75%
  • Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS (GlobeNewswire) +6.13%
  • Clene to Present at Upcoming Investor Conferences (GlobeNewswire)
  • Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8 NDA (GlobeNewswire)
  • Clene Announces $4 Million Registered Direct Offering (GlobeNewswire) +22.56%
  • Clene to Present at Upcoming September Investor Conferences (GlobeNewswire)
  • NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval (FinanceWire)
  • Clene to Present at the Emerging Growth Conference (GlobeNewswire)
  • Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights (GlobeNewswire)
  • Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval (GlobeNewswire)
  • Clene to Present at The Canaccord 46th Annual Growth Conference (GlobeNewswire) -5.41%
  • Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights (GlobeNewswire) +8.46%
  • Clene Announces $7 Million Underwritten Offering of Common Stock (GlobeNewswire) -18.67%
  • Clene to Present at Upcoming May Conferences (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.050-0.4540.2700.060.075
2026Q22026-08-14-1.080-0.368-1.0840.090.065
2026Q12026-05-14-0.690-0.637-0.6950.020.056
2025Q42026-03-12-0.930-0.578-0.8800.080.036
2025Q32025-11-13-0.850-0.580-0.8530.020.067
2025Q22025-08-14-0.780-0.473-0.7790.030.076
2025Q12025-05-07-0.090-0.950-0.0850.080.085
2024Q42025-03-24-1.590-0.967-1.6750.090.147
2024Q32024-11-13-1.220-1.331-0.0610.090.117
2024Q22024-08-07-1.060-1.508-1.0560.090.126
2024Q12024-05-08-1.800-1.600-1.7250.070.165
2023Q42024-03-13-0.200-1.440-1.5840.170.155
2023Q32023-11-07-0.400-1.800-0.3770.110.146
2023Q22023-08-14-5.800-2.466-5.8440.270.127
2023Q12023-05-12-3.000-2.896-3.0950.110.137
2022Q42023-03-13-0.200-0.686-0.2820.220.187

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-18.100-7.400-22.0260.200.20
2021FY-3.200-11.800-3.1640.720.60
2022FY-9.200-9.972-9.1770.460.43
2023FY-9.400-9.400-9.4350.650.61
2024FY-5.670-4.450-5.6660.340.36
2025FY-2.650-2.352-2.6500.200.14
2026FY--2.172--0.25
2027FY--1.494--26.40
2028FY-2.172--185.45
2029FY-6.115--403.41
2030FY-10.178--581.52

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-044010.070.000.12
2026Q4S2026-10-314000.080.000.17
2026Q4S2026-10-284020.080.000.17
2026Q4S2026-08-174030.080.000.17
2026Q4S2026-08-144110.090.010.17
2026Q4S2026-07-284000.090.010.19
2026Q4S2026-05-144110.090.010.19
2026Q4S2026-03-194100.090.020.17
2026Q4S2026-03-175100.070.000.17
2026Q4S2026-03-125010.060.000.17
2026Q4S2026-02-063010.030.000.10
2026Q4S2026-01-154010.050.000.10
2026Q4S2025-11-134010.050.000.10
2026Q4S2025-11-114100.060.000.10

Estimate history

EPS, annual-0.025-4.086-18.614-22.026-3.164-9.177-9.435-5.666-2.655-2.6104
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.061-1.675-0.085-0.779-0.853-0.88-0.695-1.0840.049
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000.2060.7230.4730.6540.3420.20.24
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0870.0910.0810.0270.0150.0770.0150.090.056
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0960.0990.8682.9763.1163.7386.4218.0910.8514.214
Period201720182019202020212022202320242025MRQ
Shares, quarterly137.1438.098.6689.46210.2210.8511.77812.77814.214
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.240.200.340.650.470.720.210.000.00
Cost of Goods Sold Incl. D&A1.491.541.721.831.431.191.070.900.00
Gross Profit-1.25-1.34-1.37-1.17-0.96-0.47-0.86-0.900.00
Selling, General and Administrative Excl. Other20.0021.7531.7239.3747.4549.5119.3615.430.32
Research and Development12.4112.6618.6825.2231.1327.6214.308.76-
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-21.25-23.08-33.09-40.54-48.41-49.98-20.21-16.33-0.32
Interest Expense2.902.684.064.563.300.870.950.090.00
Unusual Expense2.870.633.115.81-21.53-40.69-2.26-0.240.00
Net Income Before Taxes-26.83-26.17-39.40-49.50-29.92-10.17-18.87-16.160.02
Income Taxes0.000.000.000.000.00-0.430.410.000.00
Consolidated Net Income-26.83-26.17-39.40-49.50-29.92-9.74-19.28-16.16-0.28
Net Income From Continuing Operations-26.83-26.17-39.40-49.50-29.92-9.74-19.28-16.16-0.28
Net Income-26.83-26.17-39.40-49.50-29.92-9.74-19.28-16.16-0.28
EPS (Recurring)-1.91-2.61-5.35-8.66-13.80-12.42-23.83-18.81-4.09
EPS (Basic, Before Extraordinaries)-2.36-2.65-5.67-9.43-9.18-3.16-22.03-18.61-4.09
EPS (Diluted)-2.61-2.65-5.67-9.43-9.18-3.16-22.03-18.61-4.09
EBITDA-19.83-21.59-31.45-38.84-47.00-48.90-19.21-15.43-0.32
Non-Operating Income (Expense)0.190.220.861.400.26-0.010.030.030.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.00-0.30
Stock Option Compensation Expense4.806.387.959.128.5110.340.640.33-
Price To Sales Ratio251.46289.36107.9747.59137.85349.09765.59--
Gross Margin-526.89-669.00-401.46-179.20-203.17-64.45-416.99--
Operating Margin-8,928.57-11,541.50-9,676.32-6,198.78-10,234.46-6,912.59-9,812.62--
Net Margin-11,271.43-13,086.50-11,520.47-7,569.42-6,325.16-1,347.16-9,357.77--
Shares Outstanding14.2110.858.096.423.743.122.980.870.10
Market Capitalization63.5063.5042.3738.0963.54255.48536.3322.0819.67

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.060.090.010.080.010.030.080.09
Cost of Goods Sold Incl. D&A0.370.390.360.380.370.370.420.42
Gross Profit-0.31-0.30-0.34-0.31-0.35-0.34-0.34-0.33
Selling, General and Administrative Excl. Other6.045.051.727.195.305.533.738.32
Research and Development4.113.140.005.163.183.181.145.23
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.35-5.35-2.06-7.50-5.65-5.86-4.08-8.65
Interest Expense0.670.700.790.750.650.680.610.52
Unusual Expense-10.887.445.291.032.520.94-3.854.49
Net Income Before Taxes3.92-13.42-8.09-9.23-8.78-7.42-0.75-13.55
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income3.92-13.42-8.09-9.23-8.78-7.42-0.75-13.55
Net Income From Continuing Operations3.92-13.42-8.09-9.23-8.78-7.42-0.75-13.55
Net Income3.92-13.42-8.09-9.23-8.78-7.42-0.75-13.55
EPS (Recurring)-0.47-0.66-0.38-0.81-0.68-0.71-0.39-1.29
EPS (Basic, Before Extraordinaries)0.30-1.08-0.69-0.88-0.85-0.78-0.09-1.67
EPS (Diluted)0.05-1.08-0.69-0.88-0.85-0.78-0.09-1.67
EBITDA-6.00-4.99-1.71-7.13-5.28-5.50-3.67-8.25
Non-Operating Income (Expense)0.050.060.050.040.040.060.080.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.081.041.311.371.701.371.951.80
Price To Sales Ratio251.46386.88428.40307.66289.56130.2077.66125.60
Gross Margin-551.79-332.22-2,266.67-397.40-2,333.33-1,255.56-423.46-364.84
Operating Margin-11,333.93-5,941.11-13,740.00-9,733.77-37,653.33-21,718.52-5,032.10-9,510.99
Net Margin6,991.07-14,915.56-53,940.00-11,981.82-58,513.33-27,477.78-927.16-14,889.01
Shares Outstanding14.2112.7811.7810.8510.229.468.678.09
Market Capitalization63.5078.6558.0760.6660.6735.1226.4542.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.1912.1535.0023.3250.2959.278.790.740.00
Short Term Receivables0.590.391.342.971.612.170.000.000.00
Inventories0.040.070.040.040.040.190.030.000.00
Other Current Assets3.163.542.482.872.641.350.660.050.00
Total Current Assets8.9816.1638.8529.2054.5862.999.480.790.00
Net Property, Plant & Equipment9.1011.1213.4315.248.425.255.400.000.00
Total Investments and Advances0.060.060.060.060.060.000.0046.370.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.000.000.10
Total Assets18.1327.3452.3444.4963.0668.2414.8847.160.10
Short Term Debt Incl. Current Port. of LT Debt4.881.2820.116.980.490.380.420.000.00
Accounts Payable0.891.241.503.011.921.120.890.000.00
Income Tax Payable----0.000.160.00--
Other Current Liabilities5.007.773.723.863.6110.003.010.220.10
Total Current Liabilities10.7810.2925.3313.866.0311.674.310.220.10
Long Term Debt16.7919.5612.0524.8423.553.942.460.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-----0.26---
Other Liabilities8.166.341.572.5620.8952.033.2141.940.00
Total Liabilities35.7236.1938.9541.2650.4767.909.9942.160.10
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.0072.660.000.00
Common Equity-17.59-8.8613.393.2412.600.34-67.775.00-0.00
Total Shareholders Equity-17.59-8.8613.393.2412.600.344.895.00-0.00
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-17.59-8.8613.393.2412.600.344.895.00-0.00
Total Liabilities & Stockholders Equity18.1327.3452.3444.4963.0668.2414.8847.160.10
Book Value Per Share-1.62-1.092.090.874.040.11-78.0950.32-0.02
Tangible Book Value Per Share-1.62-1.092.090.874.040.11-78.0950.32-0.02
Full-Time Employees7976858610274---
Price to Book Ratio-4.23-176.531.78-6.8220.281,572.844.423.934.14
Return on Assets-115.13-98.90-102.25-55.63-14.84-32.95-52.08-1.17-
Return on Equity--1,738.36-595.47-377.90-150.56-721.85-326.79-11.10-
Return on Invested Capital--368.19-194.55-106.54-26.95-450.40-219.80-5.55-
Quick Ratio0.831.561.532.109.055.382.193.560.00
Current Ratio0.831.571.532.119.065.402.203.560.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-26.90-26.17-39.40-49.50-29.92-9.74-19.28-16.160.02
Depreciation1.421.501.651.711.410.960.960.85-
Other Funds (Non Cash)10.989.4913.2217.82-8.96-26.842.730.95-0.34
Funds from Operations-14.50-15.19-24.54-29.98-37.47-35.89-15.58-14.35-0.32
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.09-3.353.21-0.19-1.541.26-3.351.160.12
Income Taxes Payable----0.00-0.160.160.00-
Cash from Operating Activities-16.59-18.55-21.33-30.17-39.01-34.62-18.93-13.20-0.21
Capital Expenditures-0.08-0.04-0.02-0.33-5.18-1.33-0.39-0.290.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.006.33-1.17-4.990.000.000.00-46.00
Purchase of Investments0.000.00-6.17-6.17-24.610.000.000.00-46.00
Sale Or Maturity of Investments0.000.0012.505.0019.630.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.08-0.046.32-1.50-10.16-1.33-0.39-0.29-46.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.8810.409.3742.0911.777.8062.958.0846.95
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock18.8810.409.3742.0911.777.8062.958.0846.95
Proceedsfrom Stock Options-8.220.000.000.000.007.7962.878.0746.95
Issuance or Reduction of Debt, Net-0.36-0.38-20.820.075.4819.316.58-2.580.00
Change in Long Term Debt-0.36-0.38-20.820.075.4819.31-0.19-0.180.00
Issuance of Long Term Debt0.000.000.000.355.6119.470.000.000.00
Reduction of Long Term Debt-0.36-0.38-20.82-0.28-0.14-0.16-0.19-0.180.00
Net Financing Active Other Cash Flow0.011.509.920.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities18.5211.52-1.5342.1617.2527.1169.535.5046.95
Exchange Rate Effect0.080.10-0.13-0.00-0.03-0.090.27-0.00-
Net Change in Cash1.93-6.97-16.6710.49-31.96-8.9350.49-7.990.74
Free Cash Flow-16.67-18.59-21.34-30.50-44.19-35.96-19.32-13.49-0.21
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-0.260.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments9.899.675.945.197.927.29
Short Term Receivables1.411.183.510.590.551.32
Inventories0.040.040.050.040.060.08
Other Current Assets3.164.023.523.164.143.30
Total Current Assets14.4914.9113.028.9812.6711.98
Net Property, Plant & Equipment7.618.078.589.109.5810.08
Total Investments and Advances0.060.060.060.060.060.06
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets22.1623.0421.6618.1322.3122.12
Short Term Debt Incl. Current Port. of LT Debt13.741.232.694.882.041.39
Accounts Payable0.861.141.310.891.370.83
Other Current Liabilities2.512.482.735.004.895.36
Total Current Liabilities17.114.856.7310.788.317.57
Long Term Debt8.8621.1219.3616.7919.2719.46
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities10.9921.8514.388.167.093.64
Total Liabilities36.9747.8240.4735.7234.6730.68
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-14.81-24.78-18.81-17.59-12.36-8.55
Total Shareholders Equity-14.81-24.78-18.81-17.59-12.36-8.55
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-14.81-24.78-18.81-17.59-12.36-8.55
Total Liabilities & Stockholders Equity22.1623.0421.6618.1322.3122.12
Book Value Per Share-1.04-1.94-1.60-1.62-1.21-0.90
Tangible Book Value Per Share-1.04-1.94-1.60-1.62-1.21-0.90
Full-Time Employees---79--
Price to Book Ratio-4.23-3.85-3.04-4.85-6.67-6.82
Return on Assets-120.65-174.99-142.67-115.13-113.20-95.12
Return on Invested Capital---1,471.09--126.98-68.01
Quick Ratio0.843.071.930.831.521.57
Current Ratio0.853.071.940.831.531.58

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income3.91-13.39-8.09-9.33-8.75-7.41
Depreciation0.350.350.360.370.360.36
Other Funds (Non Cash)-9.029.267.473.284.832.73
Funds from Operations-4.76-3.79-0.26-5.68-3.55-4.31
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.161.21-4.260.81-0.42-0.41
Cash from Operating Activities-4.61-2.58-4.53-4.88-3.97-4.73
Capital Expenditures-0.05-0.000.00-0.03-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.05-0.000.00-0.03-0.010.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.956.405.322.203.252.30
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.956.405.322.203.252.30
Proceedsfrom Stock Options0.000.000.00-8.223.252.30
Issuance or Reduction of Debt, Net-0.09-0.09-0.09-0.09-0.12-0.17
Change in Long Term Debt-0.09-0.09-0.09-0.09-0.12-0.17
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.09-0.09-0.09-0.09-0.12-0.17
Net Financing Active Other Cash Flow0.000.000.000.011.500.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.866.315.232.124.632.13
Exchange Rate Effect0.02-0.010.040.020.000.06
Net Change in Cash0.213.730.75-2.760.64-2.54
Free Cash Flow-4.66-2.58-4.53-4.90-3.98-4.73

Revenue breakdown

Product2024: 237.00K 2025: 119.00K
Royalty2024: 105.00K 2025: 81.00K
United States2024: 342.00K 2025: 200.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.64%0.4M11.5M104.21K
2026-10-153.75%0.4M11.3M101.94K
2026-09-308.00%0.9M11.0M95.02K
2026-09-157.81%0.9M11.7M92.10K
2026-08-319.11%1.0M10.6M80.31K
2026-08-149.52%1.0M10.6M91.28K
2026-07-319.32%0.9M10.2M487.15K
2026-07-159.10%0.9M10.2M495.75K
2026-06-309.72%1.0M10.2M494.86K
2026-06-1510.39%1.1M10.2M489.00K
2026-05-2911.31%1.1M10.0M488.13K
2026-05-1513.30%1.3M10.0M481.86K
2026-04-309.73%0.9M9.0M78.24K
2026-04-1510.37%0.9M8.5M83.97K
2026-03-3111.75%1.0M8.3M93.86K
2026-03-1310.33%0.9M8.3M87.44K
2026-02-2710.19%0.8M8.3M168.01K
2026-02-139.25%0.8M8.3M168.89K
2026-01-309.48%0.8M8.7M186.32K
2026-01-158.76%0.8M8.6M178.95K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.104.900.000.0000.000.000.0000.0000.000
call5.000.004.901.450.0006.000.000.915-0.1040.001
call7.500.001.000.006.1740.000.000.482-0.0960.003
call10.000.004.900.007.7740.000.000.460-0.1130.003
put2.500.003.600.100.0001.000.000.0000.0000.000
put5.000.004.302.4018.3347.000.00-0.083-0.1040.001
put7.501.005.500.0011.8800.000.00-0.518-0.0950.003
put10.003.508.000.0012.9190.000.00-0.551-0.1110.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-208-KCurrent report2026-10-15SEC
2026-10-198-KCurrent report2026-10-19SEC
2026-10-13SCHEDULE 13G/ASEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-168-KCurrent report2026-09-15SEC
2026-09-16424B5SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-11SCHEDULE 13G/ASEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-08-04SCHEDULE 13GSEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05001.13M4
2026-0400908.91K10
2026-0300593.52K6
2026-020038.14K2
2026-01216.66K11.09M20
2025-12002.01M20
2025-110000

Institutional holders

Manager% owned
Empery Asset Management, LP7.17%
SCOGGIN MANAGEMENT LP4.70%
Boxer Capital Management, LLC3.74%
Ensign Peak Advisors, Inc2.72%
VANGUARD CAPITAL MANAGEMENT LLC2.61%
GEODE CAPITAL MANAGEMENT, LLC0.79%
BlackRock, Inc.0.48%
VANGUARD FIDUCIARY TRUST CO0.45%
PARSONS CAPITAL MANAGEMENT INC/RI0.26%
PEAK6 LLC0.23%

Funds

Fund% owned
iShares Core International Aggregate Bond ETF2.55%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.81%
VANGUARD EXTENDED MARKET INDEX FUND0.78%
Fidelity Extended Market Index Fund0.38%
iShares Micro-Cap ETF0.20%
Fidelity Series Total Market Index Fund0.12%
Fidelity Total Market Index Fund0.11%
Fidelity Nasdaq Composite Index Fund0.06%
VANGUARD BALANCED INDEX FUND0.02%
1290 VT Micro Cap Portfolio0.01%

OakChart. CLNN. Cached 15 minutes.